Aclarubicin is named as an intervention in 4 current clinical trials in our China register. None are recruiting at the moment. The most common phase is Phase 2/3. The sponsor with the most trials is First Affiliated Hospital of Zhejiang University (2). The most-studied condition is Lisaftoclax.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
NCT07535762 · ClinicalTrials.gov ↗ · Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)
|
Phase 2 | Not yet open | Shanghai Jiao Tong University School of Medicine | China |
|
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
NCT07535710 · ClinicalTrials.gov ↗ · Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed, Sezary Syndrome
|
Phase 1/2 | Not yet open | Shanghai Jiao Tong University School of Medicine | China |
|
Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
NCT07651163 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), Lisaftoclax
|
Phase 2/3 | By invitation | First Affiliated Hospital of Zhejiang University | China |
|
Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
NCT07651176 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Lisaftoclax
|
Phase 2/3 | By invitation | First Affiliated Hospital of Zhejiang University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| First Affiliated Hospital of Zhejiang University | 2 |
| Shanghai Jiao Tong University School of Medicine | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 0 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China register name Aclarubicin as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 4 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
First Affiliated Hospital of Zhejiang University (2) and Shanghai Jiao Tong University School of Medicine (2). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Aclarubicin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Aclarubicin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Aclarubicin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.